Compare ACADIA Pharmaceuticals Inc. (ACAD) vs ProShares Ultra Bitcoin ETF (BITU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs ProShares Ultra Bitcoin ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.52 (market cap $5.07B), while ProShares Ultra Bitcoin ETF trades at $9.25. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, ProShares Ultra Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | BITU | |
|---|---|---|
Market Cap | $5.07B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $29.41 | $64.41 |
52-Week Low | $20.06 | $8.12 |
Enterprise Value | $4.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
BITU's stock trades at $9.205, down 1.34% in the last 24 hours, with a bearish technical signal from moving averages and a neutral stance from oscillators. The company has declared several dividends in 2026, with the latest being $0.02 per share. Key support and resistance levels are tightly clustered around $9 to $10, indicating limited recent price movement.
The outlook for BITU is cautious due to bearish technical indicators and negative sentiment from financial media. Investment opportunities may exist for dividend-focused investors, but risks include potential underperformance highlighted by analysts and market volatility. The stock's proximity to support levels suggests vulnerability to further declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About ProShares Ultra Bitcoin ETF
BITU is a leveraged ETF that seeks to provide two times (2x) the daily performance of Bitcoin. It is designed for sophisticated investors looking for magnified exposure to Bitcoin’s daily price movements.
Read more on BITU →
